Filter Results
:
(488)
Show Results For
-
All HBS Web
(488)
- People (1)
- News (141)
- Research (265)
- Events (1)
- Multimedia (3)
- Faculty Publications (92)
Show Results For
-
All HBS Web
(488)
- People (1)
- News (141)
- Research (265)
- Events (1)
- Multimedia (3)
- Faculty Publications (92)
- Article
The Rise of Synthetic Colors in the American Food Industry, 1870–1940
By: Ai Hisano
This article examines how, starting in the 1870s, food manufacturers in the United States began to use standardized color, achieved by synthetic dyes, as part of their marketing strategies. The emergence of the synthetic dye industry paralleled the growth of mass...
View Details
Keywords:
Safety;
Food;
Health;
Brands and Branding;
Food and Beverage Industry;
Food and Beverage Industry;
United States
Hisano, Ai. "The Rise of Synthetic Colors in the American Food Industry, 1870–1940." Special Issue on Food and Agriculture. Business History Review 90, no. 3 (October 2016): 483–504.
- Web
2.3.1 Drug & Alcohol Policy - MBA
School’s policy on drugs and alcohol—adapted from and in accordance with other similar policies at Harvard University—reflects our concern for the health View Details
- 16 May 2019
- News
To Improve Food Inspections, Change the Way They’re Scheduled
- 16 May 2016
- HBS Case
Food Safety Economics: The Cost of a Sick Customer
Chipotle Mexican Grill’s ongoing struggle to win customers back months after a contaminated food crisis highlights the challenges companies face with keeping food safe. Chipotle has seen its shares tumble...
View Details
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
Papanikolaou, Kellogg School of Management. On balance, novel drugs with unproven chemical formulas are riskier to pursue because they are less likely to win approval from the US Food View Details
- November 1989
- Teaching Note
H.J. Heinz Co.: The Administration of Policy (A), (B), (C), and (D), Teaching Note
By: Kenneth E. Goodpaster and Thomas R. Piper
Teaching Note for (9-382-034, 035, 036, and 037).
View Details
- 09 May 2018
- Research & Ideas
A Simple Way for Restaurant Inspectors to Improve Food Safety
Restaurant inspectors can be the last line of defense between you and moldy bread. (HighLaZ) Simple tweaks to the schedules of food safety inspectors could result in hundreds of thousands of currently...
View Details
- 09 Feb 2024
- HBS Case
Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive
what may at first blush appear to be an easier fix: new drugs such as Ozempic, Wegovy, and Mounjaro, says Harvard Business School Professor Regina E. Herzlinger, who has studied the American health care...
View Details
- 09 Jul 2015
- News
Shoppers with reusable bags buy more junk food
- 01 Oct 2018
- Working Paper Summaries
Negative Shocks and Innovation: Evidence from Medical Device Recalls
- 11 Jan 2017
- Research & Ideas
The Paradoxical Quest to Make Food Look 'Natural' With Artificial Dyes
chromate was used to make milk look creamier; and various poisonous ingredients were used to create bright colors for various candies, reportedly causing some children to fall ill or even die. Hisano highlights key dates in View Details
Keywords:
by Carmen Nobel
- September 1991 (Revised February 1993)
- Case
Burroughs Wellcome and AZT (A)
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S....
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Ethics;
Business and Government Relations;
Communication Strategy;
Health Care and Treatment;
Monopoly;
Intellectual Property;
Research and Development;
Price;
Pharmaceutical Industry;
London
Emmons, Willis M., III. "Burroughs Wellcome and AZT (A)." Harvard Business School Case 792-004, September 1991. (Revised February 1993.)
- 01 Mar 2014
- News
The Solution to the Global Food Crisis Just Might Come from Nigeria
these things, people look on it as the most difficult country to change." And yet, a shift appears under way. A new reformist government has started treating agriculture as a problem to be solved by industry rather than by aid. Private...
View Details
- August 2008 (Revised September 2008)
- Supplement
The Flaxil Label (C): Debrief and Endnotes
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite...
View Details
Keywords:
Safety;
Value Creation;
Negotiation;
Health Care and Treatment;
Sales;
Pharmaceutical Industry
Barron, Greg M. "The Flaxil Label (C): Debrief and Endnotes." Harvard Business School Supplement 909-003, August 2008. (Revised September 2008.)
- April 2020
- Article
Regulatory Oversight, Causal Inference, and Safe and Effective Health Care Machine Learning
By: Ariel Dora Stern and W. Nicholson Price, II
In recent years, the applications of Machine Learning (ML) in the health care delivery setting have grown to become both abundant and compelling. Regulators have taken notice of these developments and the U.S. Food and Drug Administration (FDA) has been engaging...
View Details
Keywords:
Machine Learning;
Causal Inference;
Health Care and Treatment;
Safety;
Governing Rules, Regulations, and Reforms
Stern, Ariel Dora, and W. Nicholson Price, II. "Regulatory Oversight, Causal Inference, and Safe and Effective Health Care Machine Learning." Biostatistics 21, no. 2 (April 2020): 363–367.
- 15 Jan 2019
- First Look
New Research and Ideas, January 15, 2019
forthcoming American Journal of Therapeutics Food and Drug Administration Guidance Documents and New Medical...
View Details
Keywords:
Dina Gerdeman
- 2007
- Book
Perspectives on Risk and Regulation: The FDA at 100
By: Arthur A. Daemmrich and Joanna Radin
Perspectives on Risk and Regulation: The FDA at 100 brings together the viewpoints of Food and Drug Administration officials and industry leaders on the future of regulating food, drugs, medical devices, and dietary supplements. In a period of rapid scientific...
View Details
Keywords:
Private Sector;
Governing Rules, Regulations, and Reforms;
Policy;
Health Care and Treatment;
Business and Government Relations;
Risk and Uncertainty;
Cooperation
Daemmrich, Arthur A., and Joanna Radin, eds. Perspectives on Risk and Regulation: The FDA at 100. Chemical Heritage Foundation, 2007. (Fulltext.)
- May 2021
- Case
The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease
By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory...
View Details
Keywords:
Innovation and Invention;
Strategy;
Business or Company Management;
Society;
Health;
Public Administration Industry;
Public Administration Industry;
United States
Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.
- 2010
- Chapter
From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance
By: Arthur A. Daemmrich
Adverse drug reactions pose distinct but potentially catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Testing and Trials;
Business and Government Relations;
Risk and Uncertainty;
Safety;
Pharmaceutical Industry;
United States
Daemmrich, Arthur A. "From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance." Chap. 13 in The Fragmentation of U.S. Health Care: Causes and Solutions, edited by Einer Elhauge, 301–322. Oxford: Oxford University Press, 2010.
- 14 Nov 2017
- First Look
New Research and Ideas: November 14, 2017
authors provide numerous examples of health care organizations that are taking these steps—and seeing impressive results. Publisher's link: https://pubwww.hbs.edu/faculty/Pages/item.aspx?num=53460 forthcoming JAMA Cardiology The Central and...
View Details
Keywords:
Carmen Nobel